bisoprolol has been researched along with Cardiac Toxicity in 4 studies
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this randomized, controlled trial, 74 subjects with locally advanced breast cancer were randomly assigned to a group receiving lisinopril and bisoprolol (n=37) or to a control group (n=37)." | 9.41 | The Role of Lisinopril and Bisoprolol to Prevent Anthracycline Induced Cardiotoxicity in Locally Advanced Breast Cancer Patients. ( Abdurahman, M; Azhar, Y; Hidayat, S; Wihandono, A, 2021) |
| "In this randomized, controlled trial, 74 subjects with locally advanced breast cancer were randomly assigned to a group receiving lisinopril and bisoprolol (n=37) or to a control group (n=37)." | 5.41 | The Role of Lisinopril and Bisoprolol to Prevent Anthracycline Induced Cardiotoxicity in Locally Advanced Breast Cancer Patients. ( Abdurahman, M; Azhar, Y; Hidayat, S; Wihandono, A, 2021) |
| " We aimed to review the published and ongoing researches on cardioprevention strategies and to present the SAFE trial (CT registry ID: NCT2236806; EudraCT number: 2015-000914-23)." | 2.55 | SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab. ( Airoldi, M; Allegrini, G; Amoroso, D; Barletta, G; Barni, S; Becherini, C; Bengala, C; Curigliano, G; Desideri, I; Galanti, G; Guarneri, V; Livi, L; Marchetti, P; Martella, F; Meattini, I; Piovano, P; Tarquini, R; Terziani, F; Vannini, A, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wihandono, A | 1 |
| Azhar, Y | 1 |
| Abdurahman, M | 1 |
| Hidayat, S | 1 |
| Meattini, I | 1 |
| Curigliano, G | 1 |
| Terziani, F | 1 |
| Becherini, C | 1 |
| Airoldi, M | 1 |
| Allegrini, G | 1 |
| Amoroso, D | 1 |
| Barni, S | 1 |
| Bengala, C | 1 |
| Guarneri, V | 1 |
| Marchetti, P | 1 |
| Martella, F | 1 |
| Piovano, P | 1 |
| Vannini, A | 1 |
| Desideri, I | 1 |
| Tarquini, R | 1 |
| Galanti, G | 1 |
| Barletta, G | 1 |
| Livi, L | 1 |
| Higa, A | 1 |
| Hoshi, H | 1 |
| Yanagisawa, Y | 1 |
| Ito, E | 1 |
| Morisawa, G | 1 |
| Imai, JI | 1 |
| Watanabe, S | 1 |
| Takagi, M | 1 |
| Das, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of ACE Inhibitors and Beta Blockers as Cardiotoxicity Prevention in Breast Cancer Patients Treated With (Neo)Adjuvant Anthracyclines and/or Trastuzumab: a Four Arm, Placebo Control, Randomized Trial[NCT02236806] | Phase 3 | 262 participants (Actual) | Interventional | 2015-07-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for bisoprolol and Cardiac Toxicity
| Article | Year |
|---|---|
SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bisoprolol; Breast Neoplasms; Cardio | 2017 |
1 trial available for bisoprolol and Cardiac Toxicity
| Article | Year |
|---|---|
The Role of Lisinopril and Bisoprolol to Prevent Anthracycline Induced Cardiotoxicity in Locally Advanced Breast Cancer Patients.
Topics: Adult; Anthracyclines; Bisoprolol; Breast Neoplasms; Cardiotoxicity; Drug Therapy, Combination; Fema | 2021 |
2 other studies available for bisoprolol and Cardiac Toxicity
| Article | Year |
|---|---|
Evaluation system for arrhythmogenic potential of drugs using human-induced pluripotent stem cell-derived cardiomyocytes and gene expression analysis.
Topics: Amlodipine; Arrhythmias, Cardiac; Benzimidazoles; Biphenyl Compounds; Bisoprolol; Cardiotoxicity; Ce | 2017 |
Small benefits in trastuzumab-related cardiotoxicity.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Age | 2017 |